Compare BSY & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSY | JAZZ |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 10.8B |
| IPO Year | 2020 | 2007 |
| Metric | BSY | JAZZ |
|---|---|---|
| Price | $39.80 | $166.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $56.73 | ★ $199.20 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | $1,460,019,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $11.30 | $6.00 |
| Revenue Next Year | $10.23 | $6.84 |
| P/E Ratio | $48.23 | ★ N/A |
| Revenue Growth | ★ 11.12 | 4.14 |
| 52 Week Low | $36.51 | $95.49 |
| 52 Week High | $59.25 | $182.99 |
| Indicator | BSY | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 29.44 | 54.70 |
| Support Level | $39.90 | $164.39 |
| Resistance Level | $40.77 | $172.00 |
| Average True Range (ATR) | 0.90 | 4.36 |
| MACD | 0.10 | -1.54 |
| Stochastic Oscillator | 5.05 | 43.84 |
Bentley Systems is a software vendor that caters to engineers, architects, constructors, and geospatial professionals by enabling design, modeling, simulation, project management, and data management of infrastructure assets. The firm delivers solutions via the cloud, desktop, and hybrid environments. While Bentley is relatively small in comparison with peers like Autodesk, it shines in core specialty areas, like bridge or rail design, as opposed to being more broad-based in its applications. Bentley's largest end market is the public works and utilities sector, which represents approximately two thirds of revenue.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.